a focused global awareness day on thrombosis, in 2014 ISTH founded the World Thrombosis Day (WTD), which takes place every year on October 13, the birthday of Rudolf Virchow. This scientist developed the concept of "thrombosis", and was a pioneer in the pathophysiology of this disease. WTD places a global spotlight on thrombosis as an urgent and growing health problem, and fo cuses attention on the following aims: 1 Highlight the burden of disease (thrombo sis in general) and highlight the need for action, specifically underscoring the unrecognized threat and serious consequences (morbidity and mor tality) related to VTE and atrial fibrillation (AF). 2 Increase public awareness of the significance, risks, and signs and symptoms of thrombosis, specifically VTE and AF as an important cause of thromboembolic stroke. 3 Empower individuals to talk with their health care providers about their risk for thrombosis and appropriate prevention. Empower individu als to seek immediate medical attention if they have signs and symptoms. 4 Galvanize organizations in countries across the globe to conduct appropriate and aligned cam paigns in their countries and regions. 5 Begin the process of advocating for "systems of care" to properly prevent, diagnose, and treat VTE and AF.
Nearly 675 organizations in 80 countries were participating in WTD in 2016, raising much needed visibility of the condition through spe cial events, educational forums, widespread me dia coverage, and social media. The Haemostasis Group of the Polish Society of Hematology and Transfusion Medicine, being a Global Partner of WTD, together with the Polish Society of Phlebol ogy, systematically implements initiatives dedi cated to the increase of the global as well as med ical staff awareness in the field of VTE preven tion, diagnosis, and treatment. One of this ini tiatives is an annually organized educative WTD symposium: this year the 3rd Conference "Venous Thromboembolism -an underestimated problem" was held on October 13, 2016, in Warsaw, Poland (www.chorobykrwi.pl) .
The discussions covered different aspects of VTE diagnosis and treatment, with much of the attention focused on direct oral anticoag ulants (DOACs), which directly inhibit either thrombin (dabigatran) or factor Xa (apixaban, To the Editor In 2012, the World Health As sembly set a global target to reduce premature deaths from noninfectious disease, including ve nous thromboembolism (VTE), by 25% by 2025. VTE, which encompasses deep vein thrombo sis (DVT) and pulmonary embolism (PE), causes significant morbidity and mortality in hospi talized and nonhospitalized patients. The esti mated total number of symptomatic VTE events (range based on probabilistic sensitivity analy sis) per annum within the 25 European Union (EU) countries with a population of 454.4 mil lion, was ~680 000 DVT events, and ~430 000 PE events. The number of VTE related deaths was estimated at ~540 000 across the EU per annum, which is more than double the number of com bined deaths due to AIDS, breast cancer, prostate cancer, and transport accidents.
1 Almost three quarters of all VTE related deaths were from hospital acquired VTE, and according to available evidence, PE directly accounts for 5% to 10% of all in hospital deaths. Given the availability of effec tive VTE prophylaxis, many of these events and deaths could have been prevented. In the Unit ed States, of the more than 900 000 annual cas es of VTE, at least 300 000 deaths (directly or in directly) are related to VTE, and these numbers are expected to increase, because of population aging. 2 The long term complications of VTE in clude recurrent thrombosis, postthrombotic syn drome, and chronic thromboembolic pulmonary hypertension.
The estimated total number of symptomatic VTE events in Poland was ~56 000 DVT cases, and ~35 000 PE cases per annum.
The most comprehensive systematic review of the literature on the global disease burden caused by VTE, including over 8000 citations, was pub lished in 2014 by the International Society on Thrombosis and Haemostasis (ISTH), the lead ing worldwide not for profit organization ded icated to advancing the understanding, preven tion, diagnosis, and treatment of thrombotic and bleeding disorders.
3 Studies from Western Europe, North America, Australia, and south ern Latin America (Argentina) yielded consis tent results, with annual incidence of VTE rates ranging from 0.75 to 2.69 per 1000 individu als in the population. The incidence increased to between 2 and 7 per 1000 among those aged 70 years or older. In response to requests for
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The 2016 World Thrombosis Day in Poland to provide a rational basis for the investigation and management of children aged from 1 month to 16 years with VTE, including cerebral venous thrombosis. 5 The remarkably complex subject of pathophys iology of thrombotic complications in antiphos pholipid syndrome, and in paroxysmal nocturnal hemoglobinuria has been presented by 2 lectur ers, experts in these fields.
For years, a venous thrombectomy as well as fibrinolytic treatment were dedicated mostly to the patients with lifethreatening leg ischemia of the venous origin (phlegmasia coerulea dolens). In recent years, the growing interest dedicated to the rapid vein lumen patency restoration meth ods has been observed. Despite the fact that in the most current guidelines the main way of DVT treatment remains conservative treatment (an ticoagulation), the hypothesis of so called "open vein concept" to restore not only the vein patency but also proper valve function is currently more and more widely discussed. Among the methods used in this indication, the surgical venous throm bectomy seems to have rather historical value. In the current treatment, mostly the catheter di rected as well as other percutaneous pharmaco mechanical or mechanical methods are proposed. According to the Guidelines of Society of Vascu lar Surgery and American Venous Forum as well as American Heart Association Guidelines in pa tients with proximal (iliofemoral) DVT with short disease duration (no more than 14 days), in good functional condition and with low risk of bleed ing, such a treatment can be proposed, if per formed by experienced physicians in the experi enced center.
6,7 After the vein patency restoration all underlying lesions should be subsequently cor rected by venous stent implantation. The grade of recommendation dedicated to local thrombol ysis remains still very low and further studies are needed especially focusing on the possibilities of avoiding postthrombotic syndrome (PTS) in this type of therapy. In the CAVENT study based on a 2year followup in patients treated with catheter directed thrombolysis (CDT) or anticoagulation, the reduction of the PTS occurrence in CDT group was 14.4%.
8 The new ongoing study (ATTRACT, CAVA trials) should bring more data about the ef ficacy and safety of such a treatment. In the cur rent daily clinical practice, the patient undergoing invasive DVT treatment should be strictly select ed and followed during the treatment. The new treatment modalities such as rheolytic throm bectomy (AngioJet), ultrasound enhanced CDT (EKOS) or mechanical thrombectomy devices al low to restore the vein patency in the very rap id way, limiting often the treatment of the prox imal DVT to the single session or 1day therapy.
PTS as a chronic sequela of acute DVT con cerns the large part of patients with DVT. Be side the vein valve injury, in many cases the post thrombotic obstructive changes can be ob served. The technical progress of the endovas cular medicine gives the chance for the successful edoxaban, and rivaroxaban). Slowly but steadily, there has been an increased preference for DO ACs over vitamin K antagonists (VKAs). However, pending further evidence of safety and efficacy, DOACs should be avoided in patients with cancer associated VTE, where low molecular weight heparin is the treatment of choice. A DOAC might be administered in patients with VTE due to an tiphospholipid antibodies, as an off label indica tion in the light of the observation that throm bosis still occurs in 5% to 20% of cases despite adequate use of VKAs, but these observations re quire further prospective, randomized studies. 4 All patients contemplating DOAC use must weigh the benefit of treatment against the risk of bleeding. These risk benefit considerations are particularly important for special populations, such as the elderly and those with severely com promised renal function. The different options of DOAC related bleeding complication treatment were also discussed, including information about reversal agents such as idarucizumab, andexanet alfa, and ciraparantag. The reversal agent for dab igatran, idarucizumab, is approved in Europe and available in Poland. Alternatively, andexanet al pha is being developed as a universal reversal agent for patients anticoagulated with an oral or injectable factor Xa inhibitor who experience a serious uncontrolled bleeding event or who re quire urgent or emergent surgery, and is current ly in the process of future regulatory approval by the US Food & Drug Administration.
Patients who have had an unprovoked DVT or PE are at a high risk for recurrent VTE. Risk factor for recurrent VTE were discussed, and ex tended "lifelong" anticoagulation has been rec ommended in patients with high risk of recur rence. VKAs, DOACs, aspirin, and sulodexide sig nificantly reduced the risk of recurrent VTE, with DOACs and VKA being more effective than aspi rin. The decision regarding life long anticoagula tion following an unprovoked DVT or PE should depend on the patients' risk of VTE recurrence, risk of bleeding complication, as well as the pa tients' values and preferences.
VTE is increasingly recognized in pediatric practice, and the annual incidence of VTE in chil dren has been estimated at 0.7 to 1.0 per 100 000 population. Advances in technology have im proved the survival of infants who are born pre maturely and of children in intensive care units. The incidence of VTE peaks in newborns and in fants younger than 1 year, then remains very low until adolescence, when the incidence begins to increase. In children, over 90% of events are re lated to underlying medical or surgical risk fac tors, of which central venous lines are the most important. In keeping with this, there is a high incidence of upper extremity thrombosis in chil dren. Few clinical trials have been performed in this area in this patient group, and management is largely extrapolated from adult practice. Recent ly, the British Committee for Standards in Hae matology has published guidelines with the aim endovascular revascularization even in the cas es of the complete occlusion of a long vein seg ment, with satisfactory early and longterm re sults. The venous stent implantation procedures are currently dedicated mostly to patients with proximal ilocaval obstruction of thrombotic or nonthrombotic origin. The new dedicated venous stents and further technical progress as well as the growing experience in this field (also in Po land) will open the new treatment possibilities for patients with significant quality of life worsening related to obstructive PTS changes in the prox imal vein segment. In this context, the role of the proper proximal vein diagnostic workup in patients with PTS symptoms or severe chronic venous disease complains should be emphasized. 
